Compare · AZN vs WVE
AZN vs WVE
Side-by-side comparison of AstraZeneca PLC (AZN) and Wave Life Sciences Ltd. (WVE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and WVE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $263.10B, about 254.3x WVE ($1.03B).
- WVE has been more active in the news (30 items in the past 4 weeks vs 13 for AZN).
- AZN has more recent analyst coverage (25 ratings vs 20 for WVE).
- Company
- AstraZeneca PLC
- Wave Life Sciences Ltd.
- Price
- -
- -
- Market cap
- $263.10B
- $1.03B
- 1M return
- -
- -11.30%
- 1Y return
- -
- -47.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2015
- News (4w)
- 13
- 30
- Recent ratings
- 25
- 20
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Wave Life Sciences Ltd.
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It develops WVE-120101 and WVE-120102, a stereopure therapeutic candidates, which are in Phase 1b/2a clinical trials for the treatment of Huntington's disease (HD); WVE-003, mutant huntingtin SNP3 program for the treatment of HD; WVE-004, C9orf72 program for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-N531, our Exon 53 program for the treatment of Duchenne muscular dystrophy; and ATXN3 program in SCA3. The company has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, and University of Massachusetts. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
- Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
- SVP, Group Controller Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,267 units (SEC Form 4)
Latest WVE
- SEC Form EFFECT filed by Wave Life Sciences Ltd.
- Director Wagner Heidi L sold $42,070 worth of shares (7,000 units at $6.01) as part of a pre-agreed trading plan and exercised 7,000 shares at a strike of $5.97 (SEC Form 4)
- Director Rawcliffe Adrian sold $67,183 worth of shares (12,700 units at $5.29) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- Director Tan Aik Na sold $2,596 worth of shares (432 units at $6.01) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 24,968 units (SEC Form 4)
- Director Takanashi Ken sold $23,223 worth of shares (3,864 units at $6.01) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 20,079 units (SEC Form 4)
- SEC Form 144 filed by Wave Life Sciences Ltd.
- Amendment: SEC Form SCHEDULE 13D/A filed by Wave Life Sciences Ltd.
- Wave Life Sciences Announces Completion of Redomiciliation to Delaware
- SEC Form S-8 POS filed by Wave Life Sciences Ltd.
- SEC Form S-8 POS filed by Wave Life Sciences Ltd.